Peripheral T Cell Lymphoma Clinical Trial
Official title:
Transplantation After Complete Response In Patients With T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL or PTCL not otherwise specified (NOS), each representing approximately 20 to 25% of mature T- and NK/T-cell lymphomas. Compared to their B-cell counterparts, most PTCL confer dismal prognosis. In fact, except for anaplastic lymphoma kinase (ALK)-positive systemic anaplastic large cell lymphoma (sALCL), 10-year overall survival for patients with PTCL barely exceeds 30%. Given the infrequency and the heterogeneity of these malignancies, no real consensus on first-line treatment has been established for most PTCL. The place of autologous stem cell transplantation (ASCT) as a consolidation procedure for patients with PTCL achieving a complete metabolic response after induction is still highly debated. ESMO recommendations and recent guidelines from a committee of the American Society for Blood and Marrow Transplantation currently propose ASCT as first-line therapy for transplant-eligible patients for all patients reaching at least a partial response (PR) after induction. NCCN guidelines (version 2.2017) recommend ASCT or observation in case of metabolic CR but salvage regimen in case of residual disease after induction.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05559008 -
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
|
Phase 1/Phase 2 | |
Recruiting |
NCT06083701 -
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02856997 -
Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04083495 -
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT05979792 -
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
|
Early Phase 1 | |
Recruiting |
NCT04984837 -
Study of Lacutamab in Peripheral T-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT06072131 -
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
|
Phase 3 | |
Completed |
NCT01716806 -
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
|
Phase 2 | |
Terminated |
NCT03947255 -
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04028440 -
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
|
Early Phase 1 | |
Not yet recruiting |
NCT05923502 -
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
|
||
Recruiting |
NCT05883449 -
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
|
Phase 2 | |
Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT03586999 -
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT04489264 -
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
|
||
Recruiting |
NCT06151106 -
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT02753543 -
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06089941 -
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
|